Skip to main content

Advertisement

Table 4 Relationship between tumor location and clinicopathologic factors of NSCLC patients

From: Resectable left lower lobe non–small cell lung cancer with lymph node metastasis is related to unfavorable outcomes

Characteristic Node-negative patients (pN0) Node-positive patients (pN1–2)
LLL (n = 66) Non-LLL (n = 324) P LLL (n = 41) Non-LLL (n = 196) P
Sex    0.702    0.264
 Men 47 (71.2) 223 (68.8)   25 (61.0) 137 (69.9)  
 Women 19 (28.8) 101 (31.2)   16 (39.0) 59 (30.1)  
Age    0.341    0.463
 ≤60 years 31 (47.0) 173 (53.4)   27 (65.9) 117 (59.7)  
 >60 years 35 (53.0) 151 (46.6)   14 (34.1) 79 (40.3)  
T category    0.291    1.000b
 T1 9 (13.6) 59 (18.2)   4 (9.8) 18 (9.2)  
 T2 45 (68.2) 227 (70.1)   33 (80.5) 157 (80.1)  
 T3 12 (18.2) 38 (11.7)   4 (9.8) 21 (10.7)  
N category    NA    0.170
 N1 0 0   15 (36.6) 51 (26.0)  
 N2 0 0   26 (63.4) 145 (74.0)  
TNM stage    0.445c    0.081d
 Ia/b 63 (95.5) 299 (92.3)   0 0  
 IIa/b 3 (4.5) 25 (7.7)   15 (36.6) 46 (23.5)  
 IIIa 0 0   26 (63.4) 150 (76.5)  
Histology    0.260    1.000b
 AC 30 (45.5) 183 (56.5)   26 (63.4) 124 (63.3)  
 SCC 27 (40.9) 105 (32.4)   10 (24.4) 49 (25.0)  
 Others 9 (13.6) 36 (11.1)   5 (12.2) 23 (11.7)  
Histology grade    0.023    0.256b
 G1 14 (21.2) 68 (21.0)   2 (4.9) 19 (9.7)  
 G2 13 (19.7) 117 (36.1)   10 (24.4) 66 (33.7)  
 G3 39 (59.1) 139 (42.9)   29 (70.7) 111 (56.6)  
Tumor size    <0.001    0.801
 ≤4 cm 29 (43.9) 230 (71.0)   27 (65.9) 125 (63.8)  
 >4 cm 37 (56.1) 94 (29.0)   14 (34.1) 71 (36.2)  
Pleural invasion    0.343    1.000b
 Yes 57 (86.4) 264 (81.5)   37 (90.2) 178 (90.8)  
 No 9 (13.6) 60 (18.5)   4 (9.8) 18 (9.2)  
Adjuvant chemotherapy    0.063    0.050
 Yes 9 (13.6) 78 (24.1)   30 (73.2) 111 (56.6)  
 No 57 (86.4) 246 (75.9)   11 (26.8) 85 (43.4)  
No. of MLNs dissecteda 4 (3, 17) 7.5 (3, 44) <0.001 5 (3, 14) 8 (3, 38) <0.001
  1. Abbreviations as in Tables 2 and 3
  2. aThe data are presented as medians followed by the range in the parenthese and analyzed by Mann-Whitney U test; other values are presented as the number of patients followed by the percentage in the parentheses
  3. bFisher’s exact test
  4. cComparison between patients with stages Ia/b and IIa/b NSCLC
  5. dComparison between patients with stages IIa/b and IIIa NSCLC